Targeting CLDN 18.2!

ArticleMedicine Guanlan

On November 22, Keji Pharmaceuticals announced that CT041, an autologous CAR-T candidate product that targets CLDN18.

CT041 is a potential "first-in-class" autologous CAR-T cell candidate product that targets CLDN18.

Prior to this, CT041 has been approved for clinical studies in China and the United States

The latest data from the investigator-initiated trial announced at the European Society of Medical Oncology (ESMO) in 2021 shows that CT041 has failed to receive at least 2 lines of therapy in the past, and received the Phase II recommended dose (RP2D) 2.

According to the press release, Keji Pharmaceutical has applied to the State Food and Drug Administration of China to initiate a key phase 2 clinical trial, and plans to initiate a key phase 2 clinical trial in North America in 2022

Reference materials:

[1] The Canadian clinical trial of CT041, a CAR-T product independently developed by Keji Pharmaceuticals, was approved.

(The original text has been deleted)